Balance Sheet
Accounts PayablesCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Retained Earnings: 2018-2025

  • Dr Reddys Laboratories' Retained Earnings rose 16.15% to $3.7 billion in Q1 2025 from the same period last year, while for Mar 2025 it was $3.7 billion, marking a year-over-year increase of 16.15%. This contributed to the annual value of $3.7 billion for FY2025, which is 16.15% up from last year.
  • Dr Reddys Laboratories' Retained Earnings amounted to $3.7 billion in Q1 2025, which was up 16.15% from $3.2 billion recorded in Q1 2024.
  • Dr Reddys Laboratories' 5-year Retained Earnings high stood at $3.7 billion for Q1 2025, and its period low was $2.1 billion during Q1 2021.
  • In the last 3 years, Dr Reddys Laboratories' Retained Earnings had a median value of $3.2 billion in 2024 and averaged $3.2 billion.
  • Data for Dr Reddys Laboratories' Retained Earnings shows a peak YoY increased of 21.35% (in 2024) over the last 5 years.
  • Over the past 5 years, Dr Reddys Laboratories' Retained Earnings (Quarterly) stood at $2.1 billion in 2021, then grew by 8.58% to $2.3 billion in 2022, then grew by 13.26% to $2.6 billion in 2023, then climbed by 21.35% to $3.2 billion in 2024, then rose by 16.15% to $3.7 billion in 2025.
  • Its Retained Earnings stands at $3.7 billion for Q1 2025, versus $3.2 billion for Q1 2024 and $2.6 billion for Q1 2023.